Bcr-Abl is the central driver oncogene of chronic myelogenous leukemia (CML) and subsets of B-cell acute lymphoblastic leukemia.1 It is a fusion protein, whose expression results from a chromosomal translocation of the breakpoint cluster region (BCR) and Abelson tyrosine kinase (ABL) genes. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.